(Q50564206)

15 March 2018

title

Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. (English)

1 reference

15 March 2018

1 reference

J P Larsen

1

1 reference

15 March 2018

J Boas

series ordinal

2

1 reference

15 March 2018

J E Erdal

series ordinal

3

1 reference

15 March 2018

publication date

1 September 1999

1 reference

15 March 2018

European Journal of Neurology

published in

1 reference

15 March 2018

volume

6

1 reference

15 March 2018

page(s)

539-547

1 reference

15 March 2018

issue

5

1 reference

15 March 2018

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

A radical hypothesis for neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

Mortality in people taking selegiline: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.650539.X

10.1046/J.1468-1331.1999.650539.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

10457386

1 reference

15 March 2018